Aident

Aident is an AI-powered dental scribe that automatically converts dentist dictation into structured patient notes, aiming to reduce administrative workload and burnout. The company targets underserved small-language markets in the EU, creating a 'blue ocean' opportunity. With pilot clinics active and initial EHR integration in progress, Aident is leveraging its localized approach to build a defensible position against larger, more generalized competitors.

Dentists spend 30% of their appointment time on documentation, resulting in 2-3 hours of administrative work daily after clinic hours. This administrative burden is a leading cause of burnout and a primary reason dentists leave private practice.

Aident is an AI-powered dental scribe that listens to normal dentist-patient conversation and automatically generates structured clinical notes. The dentist reviews the note in the Aident UI and syncs it to their Electronic Health Record (EHR) system with a single click. The system is designed to be EU MDR Class I certified, ensuring the clinician remains in control.

The total addressable market (TAM) for a dental AI scribe in the EU is estimated at €420M. The company's initial serviceable available market (SAM) across six target small-language markets (FI, EE, LT, LV, SI, HR) is €25M. Aident's 3-year serviceable obtainable market (SOM) goal is to reach €1.5–4M in Annual Recurring Revenue (ARR).

The primary users are dentists. The customers are dental practices, ranging from solo practitioners and small clinics (up to 5 dentists) to large, multi-location enterprise clients.

Aident's competitive advantage is its 'Blue Ocean Strategy,' focusing on small European language markets that larger competitors ignore. Its moat is built on deep support for local languages, EHR integrations, and obtaining CE certification for these smaller markets, creating a defensible position.

Current traction includes two active pilot clinics in Finland where the product is being tested. A proof-of-concept for EHR integration with Hammas has been initiated in Estonia, and an EU MDR Class I GAP analysis is underway, with certification expected by the end of June 2026.